Doccla and Happitech partner to offer remote AF monitoring

Virtual ward and remote monitoring technology provider Doccla has partnered with Happitech to bring remote monitoring of atrial fibrillation (AF) to UK homes. The number of people diagnosed with AF in the UK has increased from 1 million in 2013 to more than 1.5m in 2023, according to figures from The British Heart Foundation. Common risk factors for AF include cardiometabolic conditions and lifestyle-related factors such as hypertension, obesity, coronary artery disease, heart failure, diabetes, sleep apnoea, smoking and alcohol consumption. Following an agreement in December 2024, Doccla and Happitech are rolling out their solution which increases the detection of AF episodes post-treatment through home-based, remote monitoring, reducing the need for in-person visits or hospital readmission. Yosef Sari Harb, chief executive and founder of Happitech, said: “Partnering with Doccla is a significant step in extending the reach of our smartphone-based heart rhythm monitoring to thousands more patients across the UK. “Our goal is to enable long term AF monitoring and management as seamless as possible for both clinicians to reduce burden and waiting lists and provide patients with a good self-management tool. “Together with Doccla, we’re making AF detection and post-treatment monitoring seamless for both clinicians and patients.” The partnership combines Doccla’s end-to-end virtual care infrastructure with Happitech’s cardiac monitoring technology. Doccla’s platform is in use across more than 50% of all integrated care boards and includes onboarding, compliance monitoring, devices, logistics, seamless electronic health records (EHRs) and Care Quality Commission clinical monitoring from healthcare professionals. Happitech brings to the partnership its CE-marked, AI-powered photoplethysmography (PPG) technology, which allows patients to detect signs of AF through a smartphone without the need for wearables or additional hardware. The system supports clinical triage for interventions such as cardioversion or ablation, enables remote follow-up to detect arrhythmia recurrence after treatment, and integrates with Doccla’s clinician dashboard, ensuring that data is accessible and actionable in real time. Alex Evans, head of commercial at Doccla, said: “At Doccla, we’re committed to delivering virtual care that improves outcomes and alleviates NHS pressures. “Integrating Happitech’s innovative heart monitoring technology will enhance our remote cardiac care offering, making early detection of arrhythmias more accessible and efficient for patients and physicians alike.”